Integra LifeSciences Holdings (IART)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.09B
Last updated: Nov 17, 2026 at 4:15 PM ET
Integra LifeSciences Holdings (IART) Statistics
Integra LifeSciences Holdings (IART) has a market cap of $1.09B and an enterprise value of $2.82B. Its trailing P/E of 5.4x is below its 10-year median of 19.5x. Its net debt of $1.74B equals 159.61% of its market cap.
Total Valuation
Enterprise value is 159.61% above the market cap, as debt exceeds cash.
| Market Cap | $1.09B |
|---|---|
| Enterprise Value | $2.82B |
| Latest price (Nov 17, 2026) | $13.55 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 21, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.6x and 1.0x. Its year-end P/E ranged from 5.6x to 26.5x from 2016 to 2025.
| P/E Ratio | 5.4x |
|---|---|
| Forward P/E | 5.7x |
| P/S Ratio | 0.6x |
| Forward P/S | 0.7x |
| P/B Ratio | 1.0x |
| P/FCF Ratio | 12.2x |
| P/OCF Ratio | 7.7x |
| PEG Ratio | 1.1 |
Enterprise Valuation
Counting debt and cash, the company is valued at 10.9x EBITDA and 32.5x free cash flow.
| EV / Earnings | 216.9x |
|---|---|
| EV / Sales | 1.7x |
| EV / EBITDA | 10.9x |
| EV / EBIT | 29.2x |
| EV / FCF | 32.5x |
Price Statistics
The stock is up 15.32% over 52 weeks and trades 4.64% below its 50-day average.
| Beta (1Y) | 1.57 |
|---|---|
| 52-Week Change | +15.32% |
| 1-Month Change | +0.74% |
| 3-Month Change | -21.40% |
| 6-Month Change | -5.77% |
| 5-Year Change | -80.82% |
| 10-Year Change | -67.93% |
| Total Return (1Y) | +15.32% |
| Total Return (3Y CAGR) | -29.54% |
| Total Return (5Y CAGR) | -27.58% |
| Return vs SPY (1Y) | +7.09% |
| Max Drawdown (1Y) | -40.35% |
| Max Drawdown (3Y) | -80.31% |
| Sharpe Ratio (1Y) | 0.28 |
| Correlation with SPY (1Y) | 0.35 |
| 50-Day Average | $14.21 |
| 200-Day Average | $14.21 |
| 52-Week Range | $8.70 to $20.49 |
| RSI (14 Days) | 47.2 |
| Average Volume (20 Days) | 1.23M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.62x current liabilities, and total debt is 1.86x shareholder equity.
| Current Ratio | 3.62x |
|---|---|
| Quick Ratio | 2.21x |
| Debt / Equity | 1.86x |
| Debt / EBITDA | 7.80x |
| Debt / FCF | 23.17x |
| Interest Coverage | 1.05x |
Returns and Efficiency
Return on invested capital is 2.06% over the last 12 months, against a 5-year average of 0.22%.
| Return on Equity (ROE) | 1.22% |
|---|---|
| Return on Assets (ROA) | 0.37% |
| Return on Invested Capital (ROIC) | 2.06% |
| Return on Capital Employed (ROCE) | 3.04% |
| ROE (5Y Average) | -5.13% |
| ROA (5Y Average) | -0.72% |
| ROIC (5Y Average) | 0.22% |
| Asset Turnover | 0.46x |
| Inventory Turnover | 1.65x |
| Receivables Turnover | 6.42x |
| Cash Conversion Cycle | 244 days |
Taxes
Income tax took 41.67% of pretax income over the last 12 months.
| Income Tax (TTM) | $9.30M |
|---|---|
| Effective Tax Rate | 41.67% |
Scores
IART has an Altman Z-Score of 1.29, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.29 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $1.66B over the last 12 months is up 0.84% from the 12 months before.
| Revenue | $1.66B |
|---|---|
| Revenue Growth (YoY) | +0.84% |
| Gross Profit | $867.46M |
| Operating Income | $72.69M |
| Pretax Income | $22.31M |
| Net Income | $13.01M |
| EBITDA | $254.82M |
| EBIT | $96.67M |
| Reported EPS (TTM) | $2.52 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 30.48% of the $3.51B in total assets.
| Cash and Equivalents | $252.26M |
|---|---|
| Total Debt | $1.99B |
| Net Debt | $1.74B |
| Net Debt Per Share | $22.43 |
| Working Capital | $860.94M |
| Shareholder Equity | $1.07B |
| Book Value Per Share | $13.78 |
| Tangible Book Value | -$581.85M |
| Total Assets | $3.51B |
| Total Liabilities | $2.44B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $54.62M of capital spending, operating cash flow left $85.78M of free cash flow.
| Operating Cash Flow | $140.40M |
|---|---|
| Capital Expenditures | $54.62M |
| Free Cash Flow | $85.78M |
| FCF Per Share | $1.10 |
| Depreciation and Amortization | $158.15M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 4.39%, against a 5-year average of 1.39%.
| Gross Margin | 52.36% |
|---|---|
| Operating Margin | 4.39% |
| Pretax Margin | 1.35% |
| Net Margin | 0.79% |
| EBITDA Margin | 15.38% |
| EBIT Margin | 5.83% |
| FCF Margin | 5.18% |
| Gross Margin (5Y Average) | 57.31% |
| Operating Margin (5Y Average) | 1.39% |
| Net Margin (5Y Average) | -1.01% |
Growth
Revenue grew 1.63% a year over 3 years, and EPS fell 12.77% a year.
| Revenue Growth (3Y CAGR) | +1.63% |
|---|---|
| Revenue Growth (5Y CAGR) | +3.57% |
| EPS Growth (3Y CAGR) | -12.77% |
| EPS Growth (5Y CAGR) | -1.86% |
| Book Value Per Share Growth (2Y CAGR) | -18.11% |
Dividends and Yields
IART does not pay a dividend. Its free cash flow yield is 8.18%.
| Earnings Yield | 18.52% |
|---|---|
| FCF Yield | 8.18% |
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 2-for-1 forward split on Jan 4, 2017.
| Last Split Date | Jan 4, 2017 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 6 similar companies, IART has the lowest P/E.
P/E RatioPeer median 34.5x
P/S RatioPeer median 5.0x
ROICPeer median -18.01%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +15.12%
| P/E Ratio | 5.4x vs 34.5x median |
|---|---|
| P/S Ratio | 0.6x vs 5.0x median |
| ROIC | 2.06% vs -18.01% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +0.84% vs +15.12% median |
Analyst Forecast
Consensus estimates put revenue growth at 1.20% and EPS growth at 3.08% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +1.20% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +3.08% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IART
What is IART's market cap?
Integra LifeSciences Holdings has a market cap of $1.09B. Its enterprise value, which adds debt and subtracts cash, is $2.82B.
What is IART's P/E ratio?
Integra LifeSciences Holdings has a trailing P/E ratio of 5.4x and a forward P/E of 5.7x.
How many shares of IART are outstanding?
Integra LifeSciences Holdings has 77.39M shares outstanding. The count is up 0.83% from a year earlier.
Does IART pay a dividend?
No. Integra LifeSciences Holdings does not pay a dividend.
How much debt does IART have?
Integra LifeSciences Holdings has $1.99B of total debt and $252.26M of cash and equivalents, a net debt position of $1.74B.
IART pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors